Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors

Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors

Protein kinases have emerged as crucial targets for cancer therapy over the last decades. Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials. We previously repo...

Full description

Bibliographic Details
Main Authors: Cinzia Maria Francini, Francesca Musumeci, Anna Lucia Fallacara, Lorenzo Botta, Alessio Molinari, Roberto Artusi, Laura Mennuni, Adriano Angelucci, Silvia Schenone
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:Molecules
Subjects:
aminoimidazole
SFK inhibitors
neuroblastoma
anticancer
tyrosine kinases
Online Access:http://www.mdpi.com/1420-3049/23/9/2369

Internet

http://www.mdpi.com/1420-3049/23/9/2369

Similar Items